PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology
BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it will be presenting at the 28^th Annual Congress of the World Muscle Society, being held October 3-7 in Charleston, South Carolina. Details of the presentations can be found below:*28*^th* Annual Congress of the World Muscle Society, being held October 3-7 in Charleston, South Carolina*
*Title:* Phase 1 Study of PGN-EDO51 Demonstrates Tolerability, Delivery, and High Levels of Exon Skipping for Treatment of Duchenne Muscular Dystrophy (DMD)
*Poster Number:* P44
*Location: *Ballroom A-C
*Date & Time:* October 4^th at 2:30-3:30pm EDT
*Presenter:* Michelle Mellion, M.D., Senior Vice President, Head of Clinical Development
*Title:* Single – and Repeat – Dose Nonclinical Data for PGN-EDO51 Demonstrate Potential for the Treatment of Duchenne Muscular Dystrophy (DMD)
*Poster Number:* P25
*Location: *Ballroom A-C
*Date & Time:* October 4^th at 5:15-6:15pm EDT
*Presenter:* Ashling Holland, Ph.D., Director, Preclinical Development
*Title:* CONNECT-EDO51: Trial Designs to Support the Development of PGN-EDO51 for Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
*Poster Number:* P26
*Location: *Ballroom A-C
*Date & Time:* October 4^th at 5:15-6:15pm EDT
*Presenter:* Michelle Mellion, M.D., Senior Vice President, Head of Clinical Development
*Title:* Three Novel Enhanced Delivery Oligonucleotide Candidates for Duchenne Muscular Dystrophy Mediate High Levels of Exon 53, 45, and 44 Skipping
*Poster Number:* P27
*Location: *Ballroom A-C
*Date & Time:* October 4^th at 5:15-6:15pm EDT
*Presenter:* Ashling Holland, Ph.D., Director, Preclinical Development
*Title:* PGN-EDODM1 Nonclinical Data Demonstrate Mechanistic and Meaningful Activity for Potential Treatment of Myotonic Dystrophy Type 1 (DM1)
*Poster Number:* P390
*Location: *Ballroom A-C
*Date & Time:* October 6^th at 2:00-3:00pm EDT
*Presenter:* Ashling Holland, Ph.D., Director, Preclinical Development
*Title:* Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PGN-EDODM1 in Adults with Myotonic Dystrophy Type 1 (DM1)
*Poster Number:* P391
*Location: *Ballroom A-C
*Date & Time:* October 6^th at 2:00-3:00pm EDT
*Presenter:* Jennifer Shoskes, Pharm.D., Associate Director, Clinical Development*About PepGen*PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases.
*Forward-Looking Statements*
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the potential therapeutic benefits and safety profile of our product candidates, initiation and timeline of the Phase 1 study of PGN-EDODM1, the possible benefits conferred by orphan drug designation, and planned regulatory interactions in the U.S. and elsewhere.
Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to that we may experience delays or fail to successfully initiate or complete our planned clinical trials for P PGN-EDODM1; our interpretation of clinical and preclinical study results may be incorrect; our product candidates may not be safe and effective; there may be delays in regulatory review, clearance to proceed or approval by regulatory authorities with respect to our programs, including clearance to commence planned clinical studies of our product candidates, including PGN-EDODM1, and to resolve the FDA clinical hold for the proposed Phase 1 clinical trial of PGN-EDODM1; changes in regulatory framework that are out of our control; and we are dependent on third parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning PepGen’s programs and operations are described in our most recent annual report on Form 10-K and quarterly report on Form 10-Q that are filed with the SEC. PepGen explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
*Investor Contact
*Laurence Watts
Gilmartin Group
Laurence@gilmartinir.com
*Media Contact
*Sarah Sutton
Argot Partners
pepgen@argotpartners.com